WINDTREE THERAPEUTICS INC /DE/ (WINT): debt financing — Windtree Therapeutics issues $1.6M in senior convertible notes due 2026 with 10% interest and dilutive conversion terms

WINDTREE THERAPEUTICS INC /DE/

Issued $1.6M aggregate principal in senior convertible promissory notes due Oct 9, 2026 to institutional investors.
Notes bear 10% per annum interest, payable monthly starting Nov 5, 2025; principal and accrued interest due at maturity.
Conversion price set at 90% of lowest sale price over 20 consecutive trading days prior to conversion; subject to automatic adjustment if conversion price < 80% of market price.
Notes junior to existing June 2025 senior convertible note held by DFU, LLC.
25% of gross proceeds from Common Stock Purchase Agreement must prepay notes at 120% premium; full prepayment required upon qualified equity financing of $1M+.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ incurred convertible notes of $1,600,000 with institutional investors at 10% per annum on a 360-day basis maturing October 9, 2026.

Instrument: convertible notes
Principal: $1,600,000
Counterparty: institutional investors
Rate: 10% per annum on a 360-day basis
Maturity: October 9, 2026
Event: incurrence

Exact text from the filing

On October 9, 2025, Windtree Therapeutics, Inc. (the “Company”) issued to institutional investors (collectively, “Holders” and each a “Holder”) an aggregate principal amount of $1,600,000 in senior convertible promissory notes due 2026 (the “Commitment Notes”).

View on SEC.gov

312 debt financings filed in the last 30 days. Browse all debt financings →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-25-031178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.